Written question asked by Baroness Hodge of Barking (Labour) on Friday, 15 October 2021, in the House of Commons. It was due for an answer on Tuesday, 19 October 2021. It was answered by Edward Argar (Conservative) on Thursday, 28 October 2021 on behalf of the Department of Health and Social Care.
Fampridine
- Question
-
To ask the Secretary of State for Health and Social Care, what assessment the Government has made of the potential cost savings for (a) social care and (b) welfare of making fampridine (fampyra) routinely available on the NHS.
- Answer
-
The Department has made no assessment. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service. In developing its recommendations, NICE takes account of all health and publicly funded social care costs and benefits. It does not routinely consider wider societal costs such as the impact on welfare spending.
Secondary information
- Type
- Written question
- Reference
- 56737
- Session
- 2021-22
- Subjects
- Fampridine
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2021-10-28 14:58:16 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2021-22/56737
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2021-22/56737
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2021-22/56737